DALLAS-Thursday 4 July 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- CyrusOne Inc. (NASDAQ: CONE), a leading global real estate investment trust (REIT), announced it has broken ground on the first phase of its newest data center location in Frankfurt, Germany.

The facility is CyrusOne’s third in the Sossenheim district of the city, offering cloud providers, systems integrators and multinational corporations customized, secure and resilient data center solutions within a key business hub.

Upon completion, expected in Q2 2020, the site will comprise two adjoining, four-story buildings delivering 22 MW of IT power to 11,500 sq. m of world-class technical space. Indirect adiabatic air cooling in each data hall will ensure an extremely low Power Usage Efficiency (PUE).

“Frankfurt is one of the fastest growing and most strategically important locations for CyrusOne due to its economic strength and proximity to one of the most important European financi ... Read more »

SEONGNAM, South Korea-Monday 8 July 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Smilegate Entertainment announced on July 8 that it has officially launched its dating adventure VR game, FOCUS on YOU and stealth action adventure VR game, ROGAN: The Thief in the Castle.

FOCUS on YOU is a VR game in which player, as a high school student fond of photography, can go on a date with the female character HAN YUA at virtual places including a cafe, school, and resort area, enjoying various activities such as photo shoot together.

The VR game differentiates itself with others by allowing players to form a deeper connection to HAN YUA and recall their own first love through a bunch of features like voice recognition, changing clothes, and flashback mode where players can replay certain episodes.

In ROGAN: The Thief in the Castle, a stealth action adventure VR game, the player becomes Rogan the thief and solves mysterious incidents happening in Blackstone Castle set i ... Read more »

CAMBRIDGE, Mass. & OSAKA, Japan-Monday 8 July 2019 [ AETOS Wire ]

- Updated results from the Phase IIIb/IV PROPEL Study show that pharmacokinetic (PK)-driven dosing may be used to achieve FVIII target trough levels of 8–12%; and that selecting a patient-appropriate target FVIII level plus adjusting a dosing regimen to that patient’s PK characteristics, can improve the overall PK profile and may enhance outcomes, with no adverse event profile change – thus reinforcing the importance of PK-guided dosing and the potential benefit of personalized prophylaxis with ADYNOVATE1

- Data presented alongside 47 other ISTH 2019 presentations showcasing the latest developments from Takeda’s hematology gene therapy pipeline and leading Factor portfolio

- Takeda’s robust presence at ISTH underscores its commitment to progressing scientific advancements for the bleeding disorders community

(BUSINESS WIRE) -- Takeda Pharmaceutical Comp ... Read more »

 48 presentations and sessions to showcase Takeda’s hematology gene therapy pipeline and leading factor portfolio

CAMBRIDGE, Mass. & OSAKA, Japan -Wednesday 3 July 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”), the global biotechnology leader in rare diseases, will present research covering a broad range of rare bleeding disorders at the 27th Annual International Society on Thrombosis and Haemostasis Congress (ISTH), July 6-10, 2019 in Melbourne, Australia. Showcased in 10 oral presentations and 38 poster presentations, these data underscore Takeda’s pursuit of treatment innovation to achieve optimized and personalized patient care in hematology.

“At Takeda, we are proud of the hematology heritage Shire, Baxalta and Baxter built over 70 years and we plan on expanding on it through continued research and innovation, in pursuit of a world without b ... Read more »

LACHEN, Switzerland-Sunday 7 July 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- Octapharma announced that an update on the clinical development plan and pre-clinical data with SubQ-8 were presented today in a scientific symposium at the 27th International Society on Thrombosis and Haemostasis (ISTH) Congress in Melbourne, Australia. SubQ-8 combines simoctocog alfa, a human cell line-derived recombinant FVIII, with a recombinant VWF fragment dimer produced in a human cell line, in an innovative approach to facilitate uptake of subcutaneous FVIII into the circulation.

Larisa Belyanskaya, Head of Octapharma’s Haematology International Business Unit, said “We are very pleased to share the latest data and clinical development plans for SubQ-8 with the haemophilia community at the ISTH Congress. We believe that subcutaneous administration of FVIII could play an important role in aiding patients to receive a potential ‘state of the art’ treatment for haemop ... Read more »